AccelStor Debuting NeoSapphire All-Flash Array Series at GDPR in the Public Sector Conference
AccelStor, the software-defined all-flash array provider, will be demonstrating its NeoSapphire all-flash array products at the “GDPR in the Public Sector” Conference. NeoSapphire All-Flash arrays offer a worry-free and GDPR compliant storage solution. AccelStor’s software-defined storage platform provides both powerful performance and strong data protection capabilities assisting customers with heavy-load requirements to construct a secured IT infrastructure and ensure they are GDPR compliant. The NeoSapphire All-Flash Array will be on display at Old Trafford Stadium in Manchester, UK on November 8, 2017.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171101005006/en/
NeoSapphire series provides a worry-free all-flash storage solution that is fully GDPR compliant in terms of affected systems and software capabilities. (Photo: Business Wire)
The EU General Data Protection Regulations (GDPR) will take effect in May 2018 and will cover the European Union across all 28 EU members. It’s a new legal framework in the EU that aims to protect citizens regarding the possession and usage of personal data. In the UK, the requirement to be compliant will be unaffected by the planned exit from the EU in 2019.
AccelStor Vice President, David Kao, said “With the GDPR coming into effect, it’s becoming crucial for any organisation and enterprise to review their internal process of handling any personal, company or government data. This calls for a refresh of security and data protection policies as well as new efficient tools and storage platforms like NeoSapphire all-flash array.”
As demand for high performance computing grows from the trend of IOT, artificial intelligence and big data analysis, enterprises require ever more powerful IT infrastructure. Different from conventional disk arrays, generating around 400K IOPS with over 1000 hard disk drives, the NeoSapphire all-flash array (AFA) could present stunning performance with a market-leading 1 million IOPS using only 24 SSDs and utilizing only 2U of rack space*. The NeoSapphire product range, using the FlexiRemap® software technology, coupled with a shared-nothing architecture, provides a proven AFA platform for data integrity and data protection. AccelStor’s NeoSapphire high availability all-flash array products deliver 99.9999% reliability and enable comprehensive data protection across the enterprise. Furthermore, to ensure minimum RPO and RTO for IT operators, the NeoSapphire series also provides instant failover, space-efficient snapshots, snapshots backup and a worry-free active-active hardware design.
Handling personal data is the key for GDPR compliance. Steps must be taken to minimise the risk of personal identification and ensure that the data inventory is stored in a secure location and device. The data controller must conduct privacy impact assessments and implement technical measures within the GDPR principles. As an enterprise storage vendor with customers who will be within the GDPR scope, AccelStor can provide Self Encrypting Disk (SED) SSDs which provide storage level data protection and compliance with the “data at rest” section of the GDPR regulation.
Download the AccelStor
Learn more about the NeoSapphire all-flash array series
Learn more about FlexiRemap® Technology
Follow AccelStor on Twitter: @AccelStor
Follow AccelStor on Linkedin
About AccelStor, Inc.
AccelStor is accelerating the paradigm shift from conventional disk arrays to modern all-flash storage. AccelStor's NeoSapphire all-flash arrays, powered by FlexiRemap software technology, deliver sustained high IOPS for business-critical applications. With streamlined storage management, multi-protocol support, and front-access, hot-swappable solid-state drives, the NeoSapphire series promises to resolve performance bottlenecks for I/O-intensive applications like artificial intelligence, IoT, data center, virtualization, high-performance computing, database, media processing, fintech and gaming. For more information about AccelStor and NeoSapphire, please visit www.accelstor.com.
AccelStor, FlexiRemap and NeoSapphire are trademarks or registered trademarks of AccelStor, Inc. in the United States of America and/or other countries.
* IOPS test results mentioned in this press release are generated by AccelStor and may vary in different test environments.
Clara Lee, +886 2 77467616 ext. 2561
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52 | Tiedote
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50 | Tiedote
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00 | Tiedote
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 14:27 | Tiedote
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme